RGRX Stock Overview
A biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RegeneRx Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0014 |
| 52 Week High | US$0.062 |
| 52 Week Low | US$0.0004 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 100.00% |
| 33 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | 100.0% | 16.1% | 31.6% |
Return vs Industry: RGRX exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: RGRX exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| RGRX volatility | |
|---|---|
| RGRX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RGRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 3 | J. Finkelstein | www.regenerx.com |
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics.
RegeneRx Biopharmaceuticals, Inc. Fundamentals Summary
| RGRX fundamental statistics | |
|---|---|
| Market cap | US$2.11k |
| Earnings (TTM) | -US$1.69m |
| Revenue (TTM) | US$76.76k |
0.0x
P/S Ratio0.0x
P/E RatioIs RGRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGRX income statement (TTM) | |
|---|---|
| Revenue | US$76.76k |
| Cost of Revenue | US$0 |
| Gross Profit | US$76.76k |
| Other Expenses | US$1.77m |
| Earnings | -US$1.69m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RGRX perform over the long term?
See historical performance and comparison